Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Peey-Sei Kok"'
Publikováno v:
Frontiers in Urology, Vol 4 (2024)
IntroductionInduction intravesical Bacillus Calmette-Guerin (BCG) followed by maintenance after transurethral resection of bladder tumor, is the standard adjuvant therapy for high-risk non-muscle invasive bladder cancer (NMIBC). There is sparse evide
Externí odkaz:
https://doaj.org/article/8027e095e2df4e01a85a75371ae7e026
Autor:
Linda Mileshkin, Elizabeth Barnes, Tarek Meniawy, Michael Friedlander, Geraldine Goss, Jermaine Coward, Yoland Antill, Michelle Cummins, Sally Baron-Hay, Martin R Stockler, Catherine Shannon, Philip Beale, Peey-Sei Kok, Deborah Smith, Sonia Yip, Amanda Spurdle, Yeh Chen Lee, Janine Lombard, John Andrews
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial cancers (AEC)—mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR).Metho
Externí odkaz:
https://doaj.org/article/d96d05924ab04b6c8cd23204887b78f3
Autor:
Rebecca Mercieca-Bebber, Michael Friedlander, Melanie Calvert, Martin Stockler, Derek Kyte, Peey-Sei Kok, Madeleine T. King
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 1, Iss 1, Pp 1-10 (2017)
Abstract Background This study aimed to evaluate the patient-reported outcome (PRO) content of ovarian cancer randomised-controlled trial (RCT) publications, describe PRO compliance, and explore potential relationships among these and completeness of
Externí odkaz:
https://doaj.org/article/7f8f5127dc5743a7a185f17f11fee17d
Publikováno v:
Frontiers in Urology; 2024, p1-8, 8p
Autor:
Deborah Smith, Kristy P. Robledo, Sonia Yip, Michelle M. Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda Mileshkin, Yoland Antill
Publikováno v:
Cancers; Volume 15; Issue 1; Pages: 254
Women with advanced endometrial carcinoma (EC) with mismatch repair (MMR) deficiency have improved outcomes when treated with immune checkpoint inhibitors; however, additional biomarkers are needed to identify women most likely to respond. Scores for
Publikováno v:
Internal Medicine Journal.
Extrapulmonary small cell cancer (EPSCC) is a rare malignancy with an incidence of approximately 0.1%-0.4% of all cancers. Treatment of this disease is often based on small cell lung cancer.We aimed to investigate real-world clinical outcomes of pati
Autor:
Deme Karikios, Connull Leslie, Peey-Sei Kok, Nick Pavlakis, Brett G.M. Hughes, Karen Briscoe, Sonia Yip, Alistair M. Cook, Steven Kao, Wei Sen Lam, W. Joost Lesterhuis, Anna K. Nowak, Kenneth J. O'Byrne, Ailsa Langford, Martin R. Stockler, Chris Brown, Thomas John, Christos S. Karapetis
Publikováno v:
The Lancet Oncology. 21:1213-1223
Summary Background There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in
Autor:
Peey Sei Kok, Patrick M Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh Ramalingam, Alistair Cook, Willem Joost Lesterhuis, Sonia Yip, Ken O’Byrne, Nick Pavlakis, Julie Brahmer, Valsamo Anagnostou, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M Cummins, Martin Stockler, Anna K Nowak
Publikováno v:
BMJ Open, Vol 12, Iss 1 (2022)
BMJ Open
BMJ Open
IntroductionThere is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment i
Autor:
Peey-Sei Kok1 Peey-sei.kok@ctc.usyd.edu.au, Beale, Philip2, O'Connell, Rachel L.1, Grant, Peter3, Bonaventura, Tony4, Scurry, James4, Antill, Yoland5, Goh, Jeffrey6,7, Sjoquist, Katrin1,8, DeFazio, Anna9,10,11, Mapagu, Cristina9,10,11, Amant, Frederic12, Friedlander, Michael13
Publikováno v:
Journal of Gynecologic Oncology. Sep2019, Vol. 30 Issue 5, p1-14. 14p.
Autor:
Rachel G. Woodford, Deborah D.‐X. Zhou, Peey‐Sei Kok, Sally J. Lord, Michael Friedlander, Ian C. Marschner, R. John Simes, Chee Khoon Lee
Publikováno v:
CancerReferences. 128(7)
Overall survival (OS) is the gold-standard end point for oncology trials. However, the availability of multiple therapeutic options after progression and crossover to receive investigational agents confound and delay OS data maturation. Progression-f